Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516591 | 0.79 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL19194414 | 0.76 | TRPA1 (0.34) | TRPA1 | |
| SCHEMBL6363316 | 0.70 | — | — | |
| SCHEMBL9728990 | 0.68 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL5050147 | 0.66 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL15075855 | 0.66 | — | — | |
| SCHEMBL9926021 | 0.66 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL9738225 | 0.66 | NOS1 (0.42) | TRPA1 | |
| SCHEMBL30691872 | 0.66 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL2514035 | 0.66 | TRPA1 (0.33) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | claimed |
| US-7732604-B2 | Triazolopyrazine derivatives | PFIZER INC. (US) | 2010-06-08 | — | — | US | claimed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | claimed |
| US-20080070096-A1 | Proton Conducting Copolymers | STICHTING ENERGIEONDERZOEK CENTRUM NEDERLAND (NL) | 2008-03-20 | — | — | US | claimed |
| EP-1778762-B1 | PROTON CONDUCTING COPOLYMERS | STICHTING ENERGIE (NL) | 2007-12-19 | — | — | EP | claimed |
| EP-1778762-A1 | PROTON CONDUCTING COPOLYMERS | Stichting Energieonderzoek Centrum Nederland (NL) | 2007-05-02 | — | — | EP | claimed |
| WO-2006016805-A1 | PROTON CONDUCTING COPOLYMERS | STICHTING ENERGIEONDERZOEK CENTRUM NEDERLAND (NL) | 2006-02-16 | — | — | WO | claimed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | claimed |
| CN-114728867-A | Compound, organic electroluminescent element, and electronic device | 出光兴产株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-114616692-A | Organic electroluminescent element and electronic device | 出光兴产株式会社 | 2022-06-10 | — | — | CN | disclosed |
| CN-114450817-A | Organic electroluminescent element and electronic device | 出光兴产株式会社 | 2022-05-06 | — | — | CN | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-113166128-A | Novel compound and organic electroluminescent element using same | 出光兴产株式会社 | 2021-07-23 | — | — | CN | disclosed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| WO-2006016805-A1 | PROTON CONDUCTING COPOLYMERS | STICHTING ENERGIEONDERZOEK CENTRUM NEDERLAND (NL) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016805-A1 | PROTON CONDUCTING COPOLYMERS | STICHTING ENERGIEONDERZOEK CENTRUM NEDERLAND (NL) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | TRPA1 3180/4885 |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | TRPA1 3207/4885 |
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | DDX5, SAMHD1, EIF2AK2 | TRPA1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.